Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 22 February 2021, 12:11 HKT/SGT
Share:
    

Source: Eisai
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy

TOKYO, Feb 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the 18th Corporate Philanthropy Award (FY 2020) of the Japan Philanthropic Association. The presentation ceremony was held on February 19, 2021 (Friday) at the GakushiKaikan (Chiyoda-ku, Tokyo).


Award ceremony (left: Ms. Yoko Takahashi, director, the Japan Philanthropic Association, right: Keigo Kato, executive director, Knowledge Creation Dept., Eisai)


The Corporate Philanthropy Award was founded in 2003 with the aim of commending companies for their activities for social contribution that organically and sustainably utilize their management resources (human resources, know-how, technology, information, etc.) in order to solve social issues, and of passing on a fair, warm and vibrant society to the next generation by broadly disseminating those social contribution activities to society.

The award was presented to Eisai for its corporate philosophy of human health care (hhc) and its activities to realize the hhc philosophy, evaluating "a corporate culture and purposeful activities where employees demonstrate their true value toward the realization of a society in which people can live happily."

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. In 2005, Eisai stipulated this philosophy as one of its Articles of Incorporation with the support of its shareholders. As an initiative to embody this hhc philosophy, Eisai recommends all officers and employees of the Eisai Group, including outside directors, to spend 1% of their business hours with patients and to engage in "socialization" to know their emotions. In addition, for developing and emerging countries, Eisai has continuously provided a treatment for lymphatic filariasis, which is one of the neglected tropical disease (NTDs), free of charge to endemic counties through the World Health Organization (WHO). Furthermore, Eisai has adopted the tiered-pricing model for its innovative new drugs, which sets multiple tiered prices according to the patient's income level and the insurance coverage that patients could afford. Thus, we are promoting various efforts to improve access to pharmaceutical products.

Eisai will make continuous efforts, based on the hhc philosophy, to further contribute to increasing the benefits of patients and their families around the world.



Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Mar 5, 2021 16:51 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease
Mar 4, 2021 08:12 HKT/SGT
Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya
Mar 2, 2021 08:06 HKT/SGT
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong
Feb 22, 2021 14:40 HKT/SGT
Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090
Feb 15, 2021 10:07 HKT/SGT
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Feb 3, 2021 06:00 HKT/SGT
Two Immigrants, One Unique Plan For A Biopharma
Feb 1, 2021 08:35 HKT/SGT
Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea
Jan 26, 2021 10:58 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time
Jan 12, 2021 11:37 HKT/SGT
Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
Dec 18, 2020 12:09 HKT/SGT
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: